Skip to content

Cogent Biosciences, Inc. COGT Proceeds From Convertible Senior Notes

Proceeds From Convertible Senior Notes at other companies

General Purpose Acquisition Corp.
 logo
General Purpose Acquisition Corp. GPAC
$948.13K+80.6%
Lumentum Holdings Inc. logo
Lumentum Holdings Inc.LITE
$0
TeraWulf logo
TeraWulfWULF
$493.44M+305%
Microchip Technology logo
Microchip TechnologyMCHP
$0-100%
Snowflake logo
SnowflakeSNOW
$0-100%
MicroStrategy logo
MicroStrategyMSTR
$0-100%

Other financials

Income statement

See full
Operating income-$103.6M-38.3%
Net income-$97.4M-35.2%
EPS (diluted)-$0.53-1.9%

Balance sheet

See full
Cash & equivalents$241.2M+91.4%
Total debt$15.5M-9.4%
Total equity$607.7M+177%
Total assets$903.0M+218%

Cash flow

See full
Operating cash flow-$86.9M-30.6%
CapEx$449.0K-17.9%
Free cash flow-$87.3M-30.2%

Valuation

See full
Market cap$5.9B+816%
Enterprise value$5.68B+951%
P/S749.8×

Profitability

See full
Operating margin-1,044.3%
Net margin-950.4%
FCF margin-184.7%

Returns & leverage

See full
Return on equity-85.7%+1.7pp
Debt / equity-0.1×
Current ratio15.1×+10.0×

Where this comes from

Reported directly by Cogent Biosciences, Inc. in its filing.

Tagged under the XBRL concept cogt:ProceedsFromConvertibleSeniorNotes.

The official record: Cogent Biosciences, Inc.’s 10-K, filed February 17, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cogent Biosciences, Inc.'s proceeds from convertible senior notes.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cogent Biosciences, Inc.'s proceeds from convertible senior notes?
Cogent Biosciences, Inc. (COGT) reported proceeds from convertible senior notes of $55.78M in Q4 2025.
What does proceeds from convertible senior notes mean?
Represents the total cash inflows received from the issuance of debt instruments that grant the holder the option to convert the debt into equity under specified conditions. This serves as a strategic capital-raising mechanism that balances debt financing with potential future equity dilution. Investors analyze this to evaluate the company's leverage profile and long-term capital structure strategy.